SAN FRANCISCO (AFX) -- Amylin Pharmaceuticals Inc. and Eli Lilly and Co. after Wednesday's closing bell said they have submitted a supplemental new drug application to the Food and Drug Administration seeking approval for expanded use of Byetta. The application seeks approval for Byetta injection as an add-on therapy to a common class of oral diabetes medications called thiazolidinediones, in people with Type 2 diabetes who are not achieving acceptable blood sugar control, the companies added. This story was supplied by MarketWatch. For further information see www.marketwatch.com.